Qualcomm’s huge licensing victory; Avanci dominates 3G and 4G SEPs; Pharma IP deals good news; PanOptis’s $500m Apple win; PTAB danger for US innovation; plus much more
Everything we covered on IAM over the last seven days – and all you need to know from the global IP market to set yourself up for the start of another busy week
MONDAY 10th August
Half of failed IPOs on the Shanghai tech board were scuppered for reasons relating to IP deficiencies, new research has found. Read more here
A detailed examination of the 3G and 4G standard essential patents licensed through Avanci indicates that the platform is the dominant player in both markets. Read more here
Apple accuses Koss of breaching confidentiality agreement by detailing licensing discussions between the pair in a patent infringement lawsuit launched by the headphone maker. Read more here
TUESDAY 11th August
It has emerged that India’s IP office agrees in principle with an effort to abolish the Intellectual Property Appellate Board, the body that hears appeals of patent office decisions. Read more here
Over 30 US state attorney generals called upon the federal government to use so-called march-in rights to lower the price and increase supply of Gilead’s remdesivir. Read more here
In a letter to USPTO director, senate IP subcommittee chair Thom Tillis throws his weight behind proposals to increase transparency around patent ownership. Read more here
In an across-the-board victory for Qualcomm, the Court of Appeal for the Ninth Circuit has ruled that key parts of its licensing practices are not anticompetitive as had been alleged by the FTC. Read more here
WEDNESDAY 12th August
The Indian government has made a slate of appointments to fix long-vacant posts on the Intellectual Property Appellate Board despite increasing doubts about its long-term future. Read more here
How five key Asian jurisdictions – China, India, Indonesia, Japan and South Korea – are likely to approach compulsory licensing during the coronavirus crisis. Read more here
Market consensus is that the Ninth Circuit’s ruling in FTC patent licensing dispute is a big win for Qualcomm and for those who argue for limits on application of antitrust in FRAND fights. Read more here
THURSDAY 13th August
EPO oppositions filed by Huawei against Oppo patents raised eyebrows in China this week, but they don't necessarily mean patent conflict is around the corner. Read more here
Oncology licensing, smaller acquisitions and abundant venture capital provide means of commercialising life sciences innovation during covid-related M&A decline. Read more here
PanOptis’s $506 million verdict in its EDTX suit against Apple, which was announced on Tuesday, was a huge result. Read more here
FRIDAY 14th August
The top-down FRAND calculation method adopted by a Nanjing court in a dispute between Conversant and Huawei doesn’t mean doom and gloom for SEP licensors in China. Read more here
Experts in France, Germany, Italy, Spain and the UK explain how their jurisdictions are set up to apply march-in rights should viable coronavirus treatments emerge. Read more here
Probability theory says that if you allow never-ending challenges of a patent at the PTAB eventually it will be invalidated. That has the potential to wreak havoc on innovation in the US. Read more here
SATURDAY 15th August
Given the year they are having - and to paraphrase former British PM Harold Macmillan - SEP owners may never have had it so good. Read more here
